Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Damour

Showing results (271-280 of 291) with videos related to

Pageof 30
Sort By:
Plos One|February 2, 2018
Adipocyte/breast cancer cell crosstalk in obesity interferes with the anti-proliferative efficacy of tamoxifenLauriane Bougaret, Laetitia Delort, Hermine Billard, et al.
Bioorganic & Medicinal Chemistry Letters|June 8, 2000
4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activityJ M Stutzmann, G A Bohme, A Boireau, et al.
Stem Cells (Dayton, Ohio)|February 28, 2012
Pluripotent stem cell model reveals essential roles for miR-450b-5p and miR-184 in embryonic corneal lineage specificationRuby Shalom-Feuerstein, Laura Serror, Stephanie De La Forest Divonne, et al.
Bioorganic & Medicinal Chemistry|September 26, 2000
8-Methylureido-10-amino-10-methyl-imidazo[1,2-a]indeno[1,2-e] pyrazine-4-ones: highly in vivo potent and selective AMPA receptor antagonistsP Jimonet, M Chevé, G A Bohme, et al.
Bioorganic & Medicinal Chemistry Letters|March 31, 2000
8-Methylureido-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazines: highly potent in vivo AMPA antagonistsS Mignani, G A Bohme, A Boireau, et al.
Molecular Oncology|February 21, 2025
MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulationCélia Guérin, Audrey Vinchent, Marie Fernandes, et al.
Therapie|July 10, 2016
[Not Available]Pierre Noel Lirsac, Olivier Blin, Jérémy Magalon, et al.
Therapie|March 10, 2015
Creating conditions for the success of the French industrial advanced therapy sectorPierre Noel Lirsac, Olivier Blin, Jérémy Magalon, et al.
Biorxiv : the Preprint Server for Biology|November 15, 2023
MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulationCélia Guérin, Audrey Vinchent, Marie Fernandes, et al.
Pathologie-Biologie|June 10, 2008
[Human chondrocyte responsiveness to bone morphogenetic protein-2 after their in vitro dedifferentiation: potential use of bone morphogenetic protein-2 for cartilage cell therapy]V Salentey, S Claus, C Bougault, et al.
Pageof 30

Showing results (271-280 of 291) with videos related to

Sort By:
Pageof 30
Plos One|February 2, 2018
Adipocyte/breast cancer cell crosstalk in obesity interferes with the anti-proliferative efficacy of tamoxifenLauriane Bougaret, Laetitia Delort, Hermine Billard, et al.
Bioorganic & Medicinal Chemistry Letters|June 8, 2000
4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activityJ M Stutzmann, G A Bohme, A Boireau, et al.
Stem Cells (Dayton, Ohio)|February 28, 2012
Pluripotent stem cell model reveals essential roles for miR-450b-5p and miR-184 in embryonic corneal lineage specificationRuby Shalom-Feuerstein, Laura Serror, Stephanie De La Forest Divonne, et al.
Bioorganic & Medicinal Chemistry|September 26, 2000
8-Methylureido-10-amino-10-methyl-imidazo[1,2-a]indeno[1,2-e] pyrazine-4-ones: highly in vivo potent and selective AMPA receptor antagonistsP Jimonet, M Chevé, G A Bohme, et al.
Bioorganic & Medicinal Chemistry Letters|March 31, 2000
8-Methylureido-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazines: highly potent in vivo AMPA antagonistsS Mignani, G A Bohme, A Boireau, et al.
Molecular Oncology|February 21, 2025
MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulationCélia Guérin, Audrey Vinchent, Marie Fernandes, et al.
Therapie|July 10, 2016
[Not Available]Pierre Noel Lirsac, Olivier Blin, Jérémy Magalon, et al.
Therapie|March 10, 2015
Creating conditions for the success of the French industrial advanced therapy sectorPierre Noel Lirsac, Olivier Blin, Jérémy Magalon, et al.
Biorxiv : the Preprint Server for Biology|November 15, 2023
MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulationCélia Guérin, Audrey Vinchent, Marie Fernandes, et al.
Pathologie-Biologie|June 10, 2008
[Human chondrocyte responsiveness to bone morphogenetic protein-2 after their in vitro dedifferentiation: potential use of bone morphogenetic protein-2 for cartilage cell therapy]V Salentey, S Claus, C Bougault, et al.
Pageof 30